Patent ID: 11938143
Assignee: AKIRABIO, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 9:
10. The method of claim 9, wherein the second therapeutic agent is selected from the group consisting of 1-(butyryloxy)ethyl-5-amino-4-oxopentanoate (AN-233); hydroxyurea; N-[4-[4-(cyclopropylmethyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide (AG348); (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one (FT-4202); 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde (voxelotor); 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid (deferasirox); 3-hydroxy-1,2-dimethylpyridin-4-one (deferiprone); luspatercept; crizanlizumab; inclacumab; and combinations thereof.